TMS Co (TSE:4891) Other Current Liabilities: 円72.78 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4891 TMS Co Ltd TSE:4891
31 GF Score
Price 円100.00
! 1 Warning Sign
View Full Analysis

What is TMS Co Other Current Liabilities?

TMS Co TSE:4891 +1.01% 31 Other Current Liabilities is 円72.78 Mil as of Dec. 2025. GuruFocus rates TSE:4891 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

TMS Co's other current liabilities for the quarter that ended in Dec. 2025 was 円72.78 Mil.

TMS Co's quarterly other current liabilities increased from May. 2025 (円78.62 Mil) to Aug. 2025 (円108.07 Mil) but then declined from Aug. 2025 (円108.07 Mil) to Dec. 2025 (円72.78 Mil).

TMS Co's annual other current liabilities increased from Feb. 2023 (円28.16 Mil) to Feb. 2024 (円50.64 Mil) and increased from Feb. 2024 (円50.64 Mil) to Feb. 2025 (円113.65 Mil).

TMS Co Other Current Liabilities Related Terms

TMS Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for TMS Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMS Co Other Current Liabilities Chart

TMS Co Annual Data
Trend Feb21 Feb22 Feb23 Feb24 Feb25
Other Current Liabilities
66.48 115.38 28.16 50.64 113.65

TMS Co Quarterly Data
Feb21 Feb22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Feb25 May25 Aug25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.29 113.65 78.62 108.07 72.78
TSE:4891
31GF Score
TMS Co Ltd TSE:4891
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円72.78 Mil mean?
TMS Co (TSE:4891) has a Other Current Liabilities of 円72.78 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on TMS Co.
Is TMS Co's Other Current Liabilities too high?
TMS Co's current Other Current Liabilities is 円72.78 Mil. Overall, TMS Co has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's Other Current Liabilities compare to VRTX and REGN?
TMS Co's Other Current Liabilities of 円72.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on TMS Co. TMS Co's current Other Current Liabilities is 円72.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current Other Current Liabilities of 円72.78 Mil. The current Other Current Liabilities is 円72.78 Mil. TMS Co's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For TMS Co (TSE:4891), the current Other Current Liabilities is 円72.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
31GF Score

Get the complete analysis for TSE:4891

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円100.00
Price